[
    {
        "id": "osp-12289",
        "type": "article-journal",
        "title": "Ocular findings in children with acute leukemia at a tertiary care center in South America",
        "author": [
            {
                "family": "Benvenuto",
                "given": "Franco"
            },
            {
                "family": "Sgroi",
                "given": "Mariana"
            },
            {
                "family": "Guillen",
                "given": "Soledad S"
            },
            {
                "family": "Ancona",
                "given": "David"
            },
            {
                "family": "Fandiño",
                "given": "Adriana"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/ocular-findings-in-children-with-acute-leukemia-at-a-tertiary-care-center-in-south-america",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2022
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "15",
        "issue": "2",
        "page": "159-162",
        "DOI": "10.4103/ojo.ojo_347_20",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Purpose: The purpose of this study was to evaluate ophthalmological findings in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in a Latin American population.\n\nMaterials and methods: This was a single-center, retrospective study. The observational analysis was conducted in AML and ALL patients seen as a routine examination at the department of ophthalmology of tertiary care center in Argentina between March 1, 2017, and February 28, 2018.\n\nResults: Overall, 137 patients with acute leukemia were included. The mean age was 7.9 ± 5.2 years (0-18), and 55% were male (n = 75) and 45% female (n = 45). At least one-fifth (n = 31) of the patients presented some type of ocular manifestation (23%). The most frequently observed manifestation was retinal hemorrhages (n = 14), followed by papilledema (n = 9) and ocular surface involvement (n = 5). The eye involvement was more frequently identified in the AML group (24%), compared to the ALL group (22%), especially papilledema with central nervous system compromise ALL (5%) and AML (11%), P < 0.01. The presence of hemorrhages was similar in both groups. In patients with retinal hemorrhage (n = 14), the mean hematological findings were hemoglobin 7.4 ± 0.4 g/dL (6.5-8.0), erythrocytes 2.5M ± 0.3/mm3 (confidence interval [CI], 2.0-3.1), and platelets 76,000 ± 32,000/mm3 (CI, 8000-384,000). Patients without retinal findings (n = 123), the mean hematological findings were hemoglobin 9.1 ± 0.6 g/dL (8.0-10.2), erythrocytes 3.2M ± 0.6/mm3 (CI, 2.5-3.5), and platelets 92,000 ± 44,000/mm3 (CI, 42.000-390.000). Multivariable analysis found that hemoglobin levels were the most reliable predictive factor for retinal findings. It was observed that the risk diminishes in patients with levels higher than 8.5 g/dL, and that it increased in patients with levels ranging between 6.5 and 7.5 g/dL at least twice (P < 0.01).\n\nConclusions: Our results show that ocular involvement occurs in a high percentage of patients with leukemia with a clear clinical, humoral, and sometimes prognostic correlation, suggesting routine ophthalmologic evaluation in these patients."
    }
]